Immunogenicity of recombinant human erythropoietin in Korea: A two-year cross-sectional study

Shin, Sug Kyun; Moon, Sung Jin; Ha, Sung Kyu; Jo, Young Il; Lee, Tae Won; Lee, Young Sook; Kim, Yang Wook; Kim, Dae Joong; Kim, Jin Kuk; Yoo, Tae‐Hyun; Lee, Kyu Beck; Choi, Seung Ok; Kang, Ea Wha; Lee, Kang Wook; Kim, Sung Jo; Kim, Sang Kyum; Heo, Tae Hwe

doi:10.1016/j.biologicals.2012.02.003

Cited by 14 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 86–88 Recent studies have shown that anti-EPO antibody-mediated PRCA is a rare but important adverse effect in patients with CKD who take rHuEPO. 89–91 …”

Section: Causes Of Resistance To Treatment With Recombinant Human Erymentioning

confidence: 99%

See 1 more Smart Citation

Resistance of dialyzed patients to erythropoietin

Alves

Vilaça

Carvalho

et al. 2015

Revista Brasileira de Hematologia e Hemoterapia

View full text Add to dashboard Cite

Resistance to recombinant human erythropoietin is a common condition in dialyzed patients with chronic kidney disease and is associated with more hospitalizations, increased mortality and frequent blood transfusions. The main cause of hyporesponsiveness to recombinant human erythropoietin in these patients is iron deficiency. However, a high proportion of patients does not respond to treatment, even to the use of intravenous iron, which indicates the presence of other important causes of resistance. In addition to the iron deficiency, the most common causes of resistance include inflammation, infection, malnutrition, inadequate dialysis, and hyperparathyroidism, although other factors may be associated. In the presence of adequate iron stores, other causes should be investigated and treated appropriately.

show abstract

“… 86–88 Recent studies have shown that anti-EPO antibody-mediated PRCA is a rare but important adverse effect in patients with CKD who take rHuEPO. 89–91 …”

Section: Causes Of Resistance To Treatment With Recombinant Human Erymentioning

confidence: 99%

“… 87 Moreover, no commercial laboratory kit is available for the detection of anti-EPO antibodies in the clinical practice. 89 …”

Section: Causes Of Resistance To Treatment With Recombinant Human Erymentioning

confidence: 99%

Resistance of dialyzed patients to erythropoietin

Alves

Vilaça

Carvalho

et al. 2015

Revista Brasileira de Hematologia e Hemoterapia

View full text Add to dashboard Cite

show abstract

“…The letter describes the process for marketing authorization approval used in lowand middle-income countries as relying on 'a loosely designed and practised clinical study'. It is acknowledged that it is now well established that ignoring the need for appropriate assessment of quality, preclinical and clinical performance of biotherapeutics (including biosimilars) can lead to serious clinical problems: a good example of this is the high incidence of PRCA (pure red cell aplasia) development following treatment with the many EPO (erythropoietin) products which are approved in Thailand [7,8]. In any case, quality assessment, which is the foundation of the biosimilarity exercise, is normally cheaper than conducting clinical trials and so the reason for relying solely on clinical assessment seems illogical.…”

Section: Access To Safe and Eff Ective Biopharmaceuticalsmentioning

confidence: 99%

Access to safe and effective biopharmaceuticals

Thorpe¹,

Wadhwa²

2015

GaBI J

View full text Add to dashboard Cite

“…We and other researchers have used the UT-7/EPO cell line for the EPO bioassay, EPO signaling study, and EPO-mimetic drug test (Fan et al, 2006;Liu et al, 2007;Shin et al, 2010Shin et al, , 2012Kessler et al, 2012). Little information is available regarding nonpeptide small molecules with UT-7/EPO proliferative activities.…”

Section: Introductionmentioning

confidence: 99%

Biphasic Effects of Ingenol 3,20-Dibenzoate on the Erythropoietin Receptor: Synergism at Low Doses and Antagonism at High Doses

Oh¹,

Chin²,

Kim³

et al. 2015

Mol Pharmacol

Self Cite

View full text Add to dashboard Cite

Although ingenol 3,20-dibenzoate (IDB) is known as a selective novel protein kinase C (PKC) agonist, its biologic actions and underlying mechanisms remain incompletely understood. In this study, we identified IDB as a proliferative agent for an erythropoietin (EPO)-dependent cell line, UT-7/EPO, through the screening of a natural compound library. To clarify the underlying mechanism of IDB's EPO-like activities, we thoroughly analyzed the mutual relation between EPO and IDB in terms of in vitro and in vivo activities, signaling molecules, and a cellular receptor. IDB substantially induced the proliferation of UT-7/ EPO cells, but not as much as EPO. IDB also lessened the anemia induced by 5-fluorouracil in an in vivo mouse model. Interestingly, IDB showed a synergistic effect on EPO at low concentration, but an antagonistic effect at higher concentration. Physical interaction and activation of PKCs by IDB-and EPO-competitive binding of IDB to EPO receptor (EPOR) explain these synergistic and antagonistic activities, respectively. Importantly, we addressed IDB's mechanism of action by demonstrating the direct binding of IDB to PKCs, and by identifying EPOR as a novel molecular target of IDB. Based on these dual targeting properties, IDB holds promise as a new small molecule modulator of EPO-related pathologic conditions.

show abstract

Immunogenicity of recombinant human erythropoietin in Korea: A two-year cross-sectional study

Cited by 14 publications

References 23 publications

Resistance of dialyzed patients to erythropoietin

Resistance of dialyzed patients to erythropoietin

Access to safe and effective biopharmaceuticals

Biphasic Effects of Ingenol 3,20-Dibenzoate on the Erythropoietin Receptor: Synergism at Low Doses and Antagonism at High Doses

Contact Info

Product

Resources

About